

2. Hata N, Yokoyama A, Horiuchi K, et al: New 99m-Tc-(V)-DMSA tumor imaging radiopharmaceuticals with distinctive behavior from renal 99m-Tc-DMSA. *J Nucl Med* 24:P126, 1983 (abstr)
3. Ohta H, Ishii M, Yoshizumi M, et al: A comparison of the tumor-seeking agent Tc-99m(V)-DMSA and the renal imaging agent Tc-99m DMSA in humans. *Clin Nucl Med* 10:167-170, 1985
4. Petrovic J, Vanlic-Razumenic N: Biochemical studies of the renal radiopharmaceutical compound dimercaptosuccinate. *Eur J Nucl Med* 7:308-310, 1982
5. Kawamura J: Re: Increased activity in renal cell carcinoma imaged using 2,3 dimercaptosuccinic acid (lett). *J Urol* 117:354, 1977

Lamk M. Lamki
The University of Texas
M. D. Anderson Hospital & Tumor Institute
Houston, Texas

Correction

The following is a reply which was inadvertently omitted to a letter by Caballero et al. appearing in *J Nucl Med* 27:868-869, June 1986.

REPLY: Our initial ten neuroblastoma cases (1) demonstrated that the most intense MIBG uptake tended to be associated with tumors which synthesized and secreted catecholamines, but this was by no means an absolute prerequisite for tracer uptake and nonfunctioning tumors can indeed image well as Caballero et al. observed.

It is of interest to note that with pheochromocytomas there is no difference in the biochemical parameters of tumors which do and do not take up iodine-131 metaiodobenzylguanidine ([¹³¹I]MIBG), and it is quite reasonable to hypothesize that the metabolic pathways for the synthesis of catecholamines, cytoplasmic granular storage, and catecholamine

reuptake may be dissociated from one another in certain tumors. Thus, [¹³¹I]MIBG uptake has been demonstrated in nonfunctioning paragangliomas by Smit et al. (2) and we have had similar cases. Our observations suggest that the pathways are frequently, but not invariably, linked in neuroblastomas.

The "influence of previous therapy" we believe was misinterpreted by Caballero et al. In patients with tumor unresponsive to preceding radiotherapy or chemotherapy, the possibility exists that the therapy may reduce tracer uptake by the tumor in the absence of tumor shrinkage giving rise to the possibility of false-negative scans. Although the cases with the lowest tracer uptake had all been previously treated, it has been our experience that in general such therapy does not render the MIBG scan useless. We agree that [¹³¹I]MIBG scintigraphy, especially when performed serially, is very helpful in following the progress of patients on chemotherapy and radiotherapy. It may on occasion reveal tumor foci in patients who by all other available criteria are in remission. On the other hand it may also be helpful when used along with other investigations in confirming a patient to be disease-free.

References

1. Geatti O, Shapiro B, Sisson JC, et al: Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: Preliminary experience in ten cases. *J Nucl Med* 26:736-742, 1985
2. Smit AD, Van Essen LJ, Muskiet FAJ, et al: Meta-[1-131]iodobenzylguanidine uptake in a nonsecreting paraganglioma. *J Nucl Med* 25:984-986, 1984

Brahm Shapiro
 James C. Sisson
 Raymond J. Hutchinson
 William H. Beierwaltes
University of Michigan Medical Center
Ann Arbor, Michigan